| Group 1 (N = 20) | Group 2 (N = 28) | p-value |
---|---|---|---|
Presence of autoantibodies | |||
 anti-dsDNA Ab | 20 (100) | 26 (92.9) | 0.504 |
 anti-Smith Ab | 12 (63.2) | 10 (38.5) | 0.136 |
 anti-RNP Ab | 11 (57.9) | 11 (42.3) | 0.373 |
 anti-SSA Ab | 13 (68.4) | 20 (76.9) | 0.734 |
 anti-SSB Ab | 7 (36.8) | 13 (50.0) | 0.545 |
 Ever positive dRVVT | 6 (35.3) | 7 (28.0) | 0.750 |
Average laboratory tests during the follow-up period | |||
 anti-dsDNA (IU/mL), mean (SD) | 784.0 (297.7) | 434.7 (255.9) | 0.0001 |
 C3 (mg/dL), mean (SD) | 66.9 (18.7) | 86.5 (17.2) | 0.0007 |
 C4 (mg/dL), mean (SD) | 10.1 (3.5) | 14.0 (5.5) | 0.0047 |
 ESR (mm/hr), mean(SD) | 31.84 (19.57) | 22.61 (13.86) | 0.0861 |
Medication used during follow-up periodsa | |||
 Accumulated steroid dose (mg/day), median (range) | 6.2 (0.5–24.3) | 5.1 (0–15.2) | 0.085 |
 HCQ | 19 (95.0) | 28 (100) | 1 |
 CsA | 13 (65.0) | 15 (53.6) | 0.43 |
 MTX | 4 (20.0) | 2 (7.1) | 0.15 |
 MMF | 8 (40.0) | 9 (32.1) | 0.57 |
 AZA | 9 (45.0) | 12 (42.9) | 0.88 |